Previsión

No hay datos de analistas disponibles para esta empresa.

Noticias Ir al feed de noticias

WuXi XDC Cayman: major shareholder places shares to raise capital – stock falls

A major shareholder of WuXi XDC Cayman, STA Pharmaceutical Hongkong, placed 53.5 million shares at HK$73.23 each, apparently aiming to raise up to US$500 million. The news came with a substantial discount to the previous close and triggered a price drop of about 2.6% to HK$75.25. There was also profit-taking after WuXi’s strong half-year results. » Más en de.investing.com
WuXi XDC posts first-half profit above RMB 1 billion — shares rise about 15%

WuXi XDC reported H1 2026 revenue of RMB 3.7 billion (+37% year‑on‑year) and an adjusted net profit of over RMB 1 billion. Gross margin improved to 37% and order backlog rose to over USD 2 billion, including around USD 120 million of commercial orders. The stock climbed 14.8% to USD 80.15. Management reaffirmed the full-year guidance (consolidated currency‑adjusted revenue growth ~30%, standalone ≥35%) and highlighted effects from the ramp‑up of the new Singapore site and integration costs related to BioDLink. » Más en de.investing.com
WuXi XDC rises almost 12% after strong H1 results

WuXi XDC reported H1 2026 revenue of RMB 3.701 billion (+37% yoy) and an adjusted net profit attributable to shareholders of about RMB 1.027 billion (+37.4%). Gross margin improved to 37.0% and management cited the integration of BioDlink, the expansion of the global production network (including commercial production in Singapore) and the further development of its own technology platforms as drivers of structural growth. The stock then climbed roughly 12% to HK$78. » Más en de.investing.com

Datos financieros de la empresa

En el último trimestre, WuXi XDC Cayman Inc tuvo unos ingresos de 470,77 M € y un beneficio neto de 104,04 M €

(EUR)	jun 2026	YoY
Ingresos	470,77 M	-
Beneficio bruto	174,42 M	-
Beneficio neto	104,04 M	-
EBITDA	151,95 M	-

Datos fundamentales

Métrica	Valor
Capitalización bursátil	10,17 mil M €
Número de acciones	1266,36 M
Máximo/mínimo de 52 semanas	9,41 € - 4,79 €
Dividendos	No
Beta	-0,78
Ratio P/E	51,31
Ratio PEG	2,33
Ratio P/B	6,97
Ratio P/S	11,50

Perfil de la empresa

WuXi XDC Cayman Inc. ist eine Investment-Holding, die als Auftragsforschungs-, Entwicklungs- und Produktionsunternehmen in China, Nordamerika, Europa und international tätig ist. Es beschäftigt sich mit der Entdeckung, Forschung, Entwicklung und Herstellung von Antikörper-Wirkstoff-Konjugaten, Biokonjugaten, monoklonalen Antikörper-Zwischenprodukten und Nutzlast-Linkern in Verbindung mit Biokonjugaten. Das Unternehmen wurde im Jahr 2013 gegründet und hat seinen Hauptsitz in Wuxi, China. WuXi XDC Cayman Inc. ist als Tochtergesellschaft von WuXi Biologics (Cayman) Inc. tätig.